Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, is likely a factor. Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates Read More
Tirzepatide Matches Competitor’s Cardioprotective Benefits for DiabeticsTirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large… (MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) Read More
GLP-1 receptor agonist use may lower vertebral fracture risk with type 2 diabetesGLP-1 receptor agonist use may lower vertebral fracture risk with type 2 diabetes
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research letter published online Dec. 10 in JAMA Surgery. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research letter published online Dec. 10 in JAMA Read More
GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top ResearchGLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial… (MedPage Today) — As part of a longevity push, telehealth company Noom is Read More
First she got breast cancer. Then her daughter did, tooFirst she got breast cancer. Then her daughter did, too
A breast cancer diagnosis is hard enough – what happens when a mother and daughter go through it at the same time?Genna Freed should have been in the mood to celebrate. On a cloudy November day in 2022, her mother, Julie Newman, was about to complete her final round of radiation, after being diagnosed with breast cancer in September. The whole family, a close-knit bunch, was gathering with balloons and signs.But Freed, then a few weeks shy of her 31st birthday, was carrying a secret. Spurred by her mother’s diagnosis, she had her first mammogram a couple days earlier, and it had turned up a suspicious spot. Now she needed a second, diagnostic mammogram, and likely a biopsy. She found herself walking a surreal sort of tightrope, caught between relief that her mother’s treatment was over and fear that she might soon be starting her own. Continue reading…
AI Model Stratifies Late Recurrence Risk in HR-Positive Breast CancerAI Model Stratifies Late Recurrence Risk in HR-Positive Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask deep-learning algorithm that aims to estimate late distant recurrence risk in hormone receptor (HR)-positive breast…
Time Burden in Patients With Metastatic Breast and Ovarian CancerTime Burden in Patients With Metastatic Breast and Ovarian Cancer
This cohort study evaluates time demands among patients with metastatic breast and ovarian cancer.
Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast CancerBlockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer
(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…
Awareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast CancerAwareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators from an international consortium reported that knowledge of BRCA1/2 mutation status strongly influenced surgical decision-making in young patients with stages I-III breast…
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast CancerPreop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+)/HER2-negative breast cancer…